News

FDA Grants Fast Track Designation to Cue Biopharma

October 04, 2022

FDA has granted Fast Track designation for CUE-101, a treatment of recurrent/metastatic head and neck squamous cell carcinoma.

Pfizer Completes Acquisition of Biohaven Pharmaceuticals

October 04, 2022

Pfizer has completed its acquisition of Biohaven Pharmaceuticals for approximately $11.6 billion.

A Royal Tribute

October 02, 2022

Pharmaceutical Technology Europe pays tribute to the role Her Majesty Queen Elizabeth II had in promoting innovation within life sciences.

Industry’s Best Secret

October 02, 2022

One can only learn the secrets of "fight club" by attending its meetings.

Optimizing Quality

October 02, 2022

The 1VQ papers advocate for the idea that certain post-approval changes should be streamlined and expedited.

Novo Nordisk Inks $700 Million Deal with Ventus Therapeutics

September 30, 2022

Novo Nordisk will pay up to $700 million for the exclusive rights to develop and commercialize candidates from Ventus Therapeutics NLRP3 inhibitor portfolio.

FDA Approves Amylyx Pharmaceuticals Novel ALS Treatment

September 30, 2022

FDA has approved Relyrio as a once-to-twice daily treatment for patients with ALS.

Citius Pharmaceuticals Announces Clinical Collaboration with the University of Pittsburgh

September 30, 2022

Citius and the University of Pittsburgh will investigate I/ONTAK in combination with pembrolizumab for treatment of recurrent or metastatic solid tumors.

Forge Biologics Launches Plasmid DNA Manufacturing Services

September 30, 2022

Forge Biologics will offer three grades of plasmid manufacturing services at its Columbus, Ohio, location.

PerkinElmer Unveils Cell Analysis Solution

September 30, 2022

PerkinElmer has unveiled a cell analysis solution to streamline cell and gene therapy research and manufacturing.